![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Hassan Cesare Zullo Angelo Campo Salvatore MA Morini Sergio
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.15, Iss.4, 2005-04, pp. : 409-419
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Therapy of Crohn’s disease in childhood
By Beattie R Mark Bremner A Ronald F
Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel therapy for Crohn’s disease targeting IL-6 signalling
By Ito Hiroaki
Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 4, 2004-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab: a biological breakthrough in Crohn's disease therapy
Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. :